Apollo Neuro

In the press

Close-up image of Snow Apollo on a man's wrist

Apollo Neuro in the press


Init with Dr. Birnbaum

The Mood Button

Urban Health Method – Keeping Busy People Healthy

Dr. David Rabin – How Can Your Mental Health Be Affected By Illness

CEO Money

Kathryn Fantauzzi

Talent Grow Show – Developing Leaders People Want to Follow

Harnessing Neuroscience to Improve Human Resilience

For press inquiries, please contact press@apolloneuro.com

Press kit

By using this Site, I agree to its Terms & Conditions. All content downloaded from the Site (photography, audio and video, etc.) may be used for editorial purposes only. Any other use of Site content including, without limitation personal or commercial use, is strictly prohibited.

Meet the founders

Dr. David Rabin and Kathryn Fantauzzi working in their office

Apollo was co-founded in 2017 by Kathryn Fantauzzi and her husband, Dr. David Rabin, MD, PhD.

Kathryn Fantauzzi

Dedicated to innovation, Kathryn believes in getting good science out of the lab - and into people’s lives. Experienced in early-stage tech commercialization, Kathryn joined the University of Pittsburgh research team in 2016 to raise funding for clinical research on the Apollo discovery. As CEO, Kathryn has built a highly-skilled collaboration of physicians, researchers, engineers, and designers to transform the Apollo technology from a futuristic concept into a simple but powerful tool.

Dr. David Rabin, MD, PhD

Dr. David Rabin, MD, PhD, is a neuroscientist, board-certified psychiatrist, health tech entrepreneur & inventor who has been studying the impact of chronic stress in humans for more than a decade. He is the co-founder & chief medical officer at Apollo Neuroscience, which has developed the first scientifically-validated wearable technology that actively improves energy, focus & relaxation, using a novel touch therapy that signals safety to the brain. In addition to his clinical psychiatry practice, Dr. Rabin is currently conducting research on the epigenetic regulation of trauma responses and recovery to elucidate the mechanism of psychedelic-assisted psychotherapy and the neurobiology of belief.